Connective Tissue Diseases

  • Jesus Rodriguez SantamariaEmail author
  • Janyana M. D. Deonizio
  • Maira Mitsue Mukai


Connective tissue diseases share certain common traits such as skin inflammation, and joint and other structures rich in connective tissue, along with immune defects. They represent a heterogeneous group of diseases characterized by a wide variety of signs and symptoms. The autoimmune connective tissue diseases include lupus erythematous, dermatomyositis, and morphea, and are considered classic connective tissue diseases. In this chapter The Epidemiology, etiopathogenesis, clinical presentation, differential diagnosis, complementary examinations, and therapeutic approaches for connective tissue diseases are discussed.


Dermatology Skin Autoimmune connective tissue disorder Lupus Dermatomyositis Morphea Public health 


  1. 1.
    Ingvarsson RF, Bengtsson AA, Jönsen A. Variations in the epidemiology of systemic lupus erythematosus in southern Sweden. Lupus. 2016;25(7):772–80.Google Scholar
  2. 2.
    Andersen LK, Davis MD. Sex differences in the incidence of skin and skin-related diseases in Olmsted County, Minnesota, United States, and a comparison with other rates published worldwide. Int J Dermatol. 2016;55(9):939–55.Google Scholar
  3. 3.
    Fortuna G, Brennan MT. Systemic lupus erythematosus: epidemiology, pathophysiology, manifestations, and management. Dent Clin N Am. 2013;57(4):631–55.PubMedCrossRefGoogle Scholar
  4. 4.
    Jarrett P, Thornley S, Scragg R. Ethnic differences in the epidemiology of cutaneous lupus erythematosus in New Zealand. Lupus. 2016;25(13):1497–502.Google Scholar
  5. 5.
    Andersen LK, Davis MD. Prevalence of skin and skin-related diseases in the rochester epidemiology project and a comparison with other published prevalence studies. Dermatology. 2016;232:344–52.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME. The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev. 2010;9(5):A277–87.PubMedCrossRefGoogle Scholar
  7. 7.
    Pons-Estel GJ, Alarcón GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum. 2010;39(4):257–68.PubMedCrossRefGoogle Scholar
  8. 8.
    Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol. 1981;4(4):471–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Achtman JC, Werth VP. Pathophysiology of cutaneous lupus erythematosus. Arthritis Res Ther. 2015;17:182.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Squatrito D, Emmi G, Silvestri E, Ciucciarelli L, D’Elios MM, Prisco D, et al. Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedside. Auto Immun Highlights. 2014;5(2):33–45.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Choi J, Kim ST, Craft J. The pathogenesis of systemic lupus erythematosus-an update. Curr Opin Immunol. 2012;24(6):651–7.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Sullivan KE. Genetics of systemic lupus erythematosus. Clinical implications. Rheum Dis Clin N Am. 2000;26(2):229–56. v-viCrossRefGoogle Scholar
  13. 13.
    Kirchhof MG, Dutz JP. The immunopathology of cutaneous lupus erythematosus. Rheum Dis Clin N Am. 2014;40(3):455–74. viiiCrossRefGoogle Scholar
  14. 14.
    Crow MK. Developments in the clinical understanding of lupus. Arthritis Res Ther. 2009;11(5):245.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Oke V, Wahren-Herlenius M. Cutaneous lupus erythematosus: clinical aspects and molecular pathogenesis. J Intern Med. 2013;273(6):544–54.PubMedCrossRefGoogle Scholar
  16. 16.
    Cusack C, Danby C, Fallon JC, Ho WL, Murray B, Brady J, et al. Photoprotective behaviour and sunscreen use: impact on vitamin D levels in cutaneous lupus erythematosus. Photodermatol Photoimmunol Photomed. 2008;24(5):260–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Orteu CH, Sontheimer RD, Dutz JP. The pathophysiology of photosensitivity in lupus erythematosus. Photodermatol Photoimmunol Photomed. 2001;17(3):95–113.PubMedCrossRefGoogle Scholar
  18. 18.
    Eyanson S, Greist MC, Brandt KD, Skinner B. Systemic lupus erythematosus: association with psoralen – ultraviolet-A treatment of psoriasis. Arch Dermatol. 1979;115(1):54–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Rigante D, Esposito S. Infections and systemic lupus erythematosus: binding or sparring partners? Int J Mol Sci. 2015;16(8):17331–43.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Esposito S, Bosis S, Semino M, Rigante D. Infections and systemic lupus erythematosus. Eur J Clin Microbiol Infect Dis. 2014;33(9):1467–75.PubMedCrossRefGoogle Scholar
  21. 21.
    Nelson P, Rylance P, Roden D, Trela M, Tugnet N. Viruses as potential pathogenic agents in systemic lupus erythematosus. Lupus. 2014;23(6):596–605.PubMedCrossRefGoogle Scholar
  22. 22.
    SongnuanBoonsoongnern P, Faisaikarm T, Sangsuwan P, Weerachatyanukul W, Kitiyanant Y. A role of oestrogen in aggravating SLE-like syndrome in C4-deficient mice. Asian Pac J Allergy Immunol. 2015;33(4):339–48.PubMedGoogle Scholar
  23. 23.
    Lateef A, Petri M. Hormone replacement and contraceptive therapy in autoimmune diseases. J Autoimmun. 2012;38(2–3):J170–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Guettrot-Imbert G, Morel N, Le Guern V, Plu-Bureau G, Frances C, Costedoat-Chalumeau N. Pregnancy and contraception in systemic and cutaneous lupus erythematosus. Ann Dermatol Venereol. 2016;45:1084–92.Google Scholar
  25. 25.
    Pretel M, Marquès L, España A. Drug-induced lupus erythematosus. Actas Dermosifiliogr. 2014;105(1):18–30.PubMedCrossRefGoogle Scholar
  26. 26.
    Favalli EG, Sinigaglia L, Varenna M, Arnoldi C. Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus. 2002;11(11):753–5.PubMedCrossRefGoogle Scholar
  27. 27.
    Zhang N, Leng XM, Tian XP, Zhao Y, Zeng XF. Clinical analysis of 6 patients with drug-induced lupus. Zhonghua Nei Ke Za Zhi. 2016;55(3):211–5.PubMedGoogle Scholar
  28. 28.
    Privette ED, Werth VP. Update on pathogenesis and treatment of CLE. Curr Opin Rheumatol. 2013;25(5):584–90.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Sáenz-Corral CI, Vega-Memíje ME, Martínez-Luna E, Cuevas-González JC, Rodríguez-Carreón AA, de la Rosa JJ, et al. Apoptosis in chronic cutaneous lupus erythematosus, discoid lupus, and lupus profundus. Int J Clin Exp Pathol. 2015;8(6):7260–5.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Yu C, Chang C, Zhang J. Immunologic and genetic considerations of cutaneous lupus erythematosus: a comprehensive review. J Autoimmun. 2013;41:34–45.PubMedCrossRefGoogle Scholar
  31. 31.
    Moura Filho JP, Peixoto RL, Martins LG, Melo SD, Carvalho LL, Pereira AK, et al. Lupus erythematosus: considerations about clinical, cutaneous and therapeutic aspects. An Bras Dermatol. 2014;89(1):118–25.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Kuhn A, Bein D, Bonsmann G. The 100th anniversary of lupus erythematosus tumidus. Autoimmun Rev. 2009;8(6):441–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Grönhagen CM, Nyberg F. Cutaneous lupus erythematosus: an update. Indian Dermatol Online J. 2014;5(1):7–13.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Lee L, Werth V. Lupus erythematous. In: Bolognia JL, Jorizzo JL, Schaffer JV, editors. Dermatology. 2, 3 ed. Rio de Janeiro: Elsevier; 2015. p. 615–29.Google Scholar
  35. 35.
    Crowson AN, Magro CM. Cutaneous histopathology of lupus erythematosus. Diag Histopathol. 2009;15(4):157–85.CrossRefGoogle Scholar
  36. 36.
    Baltaci M, Fritsch P. Histologic features of cutaneous lupus erythematosus. Autoimmun Rev. 2009;8(6):467–73.PubMedCrossRefGoogle Scholar
  37. 37.
    Schultz HY, Dutz JP, Furukawa F, Goodfield MJ, Kuhn A, Lee LA, et al. From pathogenesis, epidemiology, and genetics to definitions, diagnosis, and treatments of cutaneous lupus erythematosus and dermatomyositis: a report from the 3rd International Conference on Cutaneous Lupus Erythematosus (ICCLE) 2013. J Invest Dermatol. 2015;135(1):7–12.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Kreuter A, Lehmann P. Relevant new insights into the effects of photoprotection in cutaneous lupus erythematosus. Exp Dermatol. 2014;23(10):712–3.PubMedCrossRefGoogle Scholar
  39. 39.
    Gordon Spratt EA, Gorcey LV, Soter NA, Brauer JA. Phototherapy, photodynamic therapy and photophoresis in the treatment of connective-tissue diseases: a review. Br J Dermatol. 2015;173(1):19–30.PubMedCrossRefGoogle Scholar
  40. 40.
    Terrier B, Derian N, Schoindre Y, Chaara W, Geri G, Zahr N, et al. Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation. Arthritis Res Ther. 2012;14(5):R221.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Böckle BC, Sepp NT. Smoking is highly associated with discoid lupus erythematosus and lupus erythematosus tumidus: analysis of 405 patients. Lupus. 2015;24(7):669–74.PubMedCrossRefGoogle Scholar
  42. 42.
    Chasset F, Francès C, Barete S, Amoura Z, Arnaud L. Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature. J Am Acad Dermatol. 2015;72(4):634–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Callen JP. Dermatomyositis Lancet. 2000 Jan 1;355(9197):53–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Callen JP, Wortmann RL. Dermatomyositis. Clin Dermatol. 2006 Sep-Oct;24(5):363–73.PubMedCrossRefGoogle Scholar
  45. 45.
    Bendewald MJ, Wetter DA, Li X, Davis MD. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County. Minnesota Arch Dermatol. 2010 Jan;146(1):26–30.PubMedGoogle Scholar
  46. 46.
    Werth VP, Callen JP, Ang G, Sullivan KE. Associations of tumor necrosis factor alpha and HLA polymorphisms with adult dermatomyositis: implications for a unique pathogenesis. J Invest Dermatol. 2002 Sep;119(3):617–20.PubMedCrossRefGoogle Scholar
  47. 47.
    Pachman LM, Veis A, Stock S, et al. Composition of calcifications in children with juvenile dermatomyositis: association with chronic cutaneous inflammation. Arthritis Rheum. 2006 Oct;54(10):3345–50.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Lutz J, Huwiler KG, Fedczyna T, et al. Increased plasma thrombospondin-1 (TSP-1) levels are associated with the TNF alpha-308A allele in children with juvenile dermatomyositis. Clin Immunol. 2002 Jun;103(3 Pt 1):260–3.PubMedCrossRefGoogle Scholar
  49. 49.
    Chen S, Wang Q, Wu Z, Wu Q, Li P, Li Y, et al. Associations between TNF-a-308A/G polymorphism and susceptibility with dermatomyositis: a meta-analysis. PLoS One. 2014;9(8):e102841.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Daoud MS, Gibson LE, Pittelkow MR. Hydroxyurea dermopathy: a unique lichenoid eruption complicating long-term therapy with hydroxyurea. J Am Acad Dermatol. 1997 Feb;36(2 Pt 1):178–82.PubMedCrossRefGoogle Scholar
  51. 51.
    Noël B. Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. J Eur Acad Dermatol Venereol. 2007 Jan;21(1):17–24.PubMedCrossRefGoogle Scholar
  52. 52.
    O’Hanlon T, Koneru B, Bayat E, Love L, Targoff I, Malley J, et al. Immunogenetic differences between Caucasian women with and those without silicone implants in whom myositis develops. Arthritis Rheum. 2004 Nov;50(11):3646–50.PubMedCrossRefGoogle Scholar
  53. 53.
    Kalus A. Rheumatologic skin disease. Med Clin N Am. 2015;99:1287–303.PubMedCrossRefGoogle Scholar
  54. 54.
    Iaccarino L, Ghirardello A, Bettio S, et al. The clinical features, diagnosis and classification of dermatomyositis. J Autoimmun. 2014;48–49:122–7.PubMedCrossRefGoogle Scholar
  55. 55.
    Katzap E, Barilla-LaBarca ML, Marder G. Antisynthetase syndrome. Curr Rheumatol Rep. 2011;13(3):175–81.PubMedCrossRefGoogle Scholar
  56. 56.
    Uribe L, Ronderos DM, Diaz MC, et al. Antisynthetase antibody syndrome: case report and review of the literature. Clin Rheumatol. 2013;32(5):715–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Hallowell RW, Danoff SK. Interstitial lung disease associated with the idiopathic inflammatory myopathies and the antisynthetase syndrome: recent advances. Curr Opin Rheumatol. 2014;26(6):684–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Koichi Y, Aya Y, Megumi U, et al. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment. Mod Rheumatol. 2015;12:1–5.Google Scholar
  59. 59.
    Yang Z, Lin F, Qin B, et al. Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol. 2015;42(2):282–91.PubMedCrossRefGoogle Scholar
  60. 60.
    Olazagasti JM, Baez PJ, Wetter DA, et al. Cancer risk in dermatomyositis: a meta-analysis of cohort studies. Am J Clin Dermatol. 2015;16(2):89–98.PubMedCrossRefGoogle Scholar
  61. 61.
    Alemo Munters L, Alexanderson H, Crofford LJ, et al. New insights into the benefits of exercise for muscle health in patients with idiopathic inflammatory myositis. Curr Rheumatol Rep. 2014;16(7):429.PubMedCrossRefGoogle Scholar
  62. 62.
    Laxer RM, Zulian F. Localized scleroderma. Curr Opin Rheumatol. 2006 Nov;18(6):606–13.PubMedCrossRefGoogle Scholar
  63. 63.
    Zulian F. Systemic manifestations in localized scleroderma. Curr Rheumatol Rep. 2004 Dec;6(6):417–24.PubMedCrossRefGoogle Scholar
  64. 64.
    Chung L, Lin J, Furst DE, Fiorentino D. Systemic and localized scleroderma. Clin Dermatol. 2006 Sep-Oct;24(5):374–92.PubMedCrossRefGoogle Scholar
  65. 65.
    Leitenberger JJ, Cayce RL, Haley RW, Adams-Huet B, Bergstresser PR, Jacobe HT. Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol. 2009 May;145(5):545–50.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Fett N, Werth VP. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2011;64(2):217–28. quiz 229–30.PubMedCrossRefGoogle Scholar
  67. 67.
    Prinz JC, Kutasi Z, Weisenseel P, Poto L, Battyani Z, Ruzicka T. “Borrelia-associated early-onset morphea”: a particular type of scleroderma in childhood and adolescence with high titer antinuclear antibodies? Results of a cohort analysis and presentation of three cases. J Am Acad Dermatol. 2009;60(2):248–55.PubMedCrossRefGoogle Scholar
  68. 68.
    Kreft B, Wohlrab J, Radant K, Danz B, Marsch WC, Fiedler E. Unrecognized radiation-induced localized scleroderma: a cause of postoperative wound-healing disorder. Clin Exp Dermatol. 2009 Oct;34(7):e383–4.PubMedCrossRefGoogle Scholar
  69. 69.
    Laetsch B, Hofer T, Lombriser N, Lautenschlager S. Irradiation-induced morphea: x-rays as triggers of autoimmunity. Dermatology. 2011;223(1):9–12.PubMedCrossRefGoogle Scholar
  70. 70.
    Eisendle K, Grabner T, Zelger B. Morphoea: a manifestation of infection with Borrelia species? Br J Dermatol. 2007 Dec;157(6):1189–98.PubMedCrossRefGoogle Scholar
  71. 71.
    Zulian F. New developments in localized scleroderma. Curr Opin Rheumatol. 2008 Sep;20(5):601–7.PubMedCrossRefGoogle Scholar
  72. 72.
    Peroni A, Zini A, Braga V, Colato C, Adami S, Girolomoni G. Drug-induced morphea: report of a case induced by balicatib and review of the literature. J Am Acad Dermatol. 2008 Jul;59(1):125–9.PubMedCrossRefGoogle Scholar
  73. 73.
    Igarashi A, Nashiro K, Kikuchi K, et al. Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. J Invest Dermatol. 1996 Apr;106(4):729–33.PubMedCrossRefGoogle Scholar
  74. 74.
    Kikuchi K, Kadono T, Ihn H, et al. Growth regulation in scleroderma fibroblasts: increased response to transforming growth factor-beta 1. J Invest Dermatol. 1995 Jul;105(1):128–32.PubMedCrossRefGoogle Scholar
  75. 75.
    Leask A, Denton CP, Abraham DJ. Insights into the molecular mechanism of chronic fibrosis: the role of connective tissue growth factor in scleroderma. J Invest Dermatol. 2004 Jan;122(1):1–6.PubMedCrossRefGoogle Scholar
  76. 76.
    Yamane K, Ihn H, Kubo M, et al. Increased serum levels of soluble vascular cell adhesion molecule 1 and E-selectin in patients with localized scleroderma. J Am Acad Dermatol. 2000 Jan;42(1 Pt 1):64–9.PubMedCrossRefGoogle Scholar
  77. 77.
    Fawzi MM, Tawfik SO, Eissa AM, El-Komy MH, Abdel-Halim MR, Shaker OG. Expression of insulin-like growth factor-I in lesional and nonlesional skin of patients with morphoea. Br J Dermatol. 2008 Jul;159(1):86–90.PubMedCrossRefGoogle Scholar
  78. 78.
    Tomimura S, Ogawa F, Iwata Y, Komura K, Hara T, Muroi E. Autoantibodies against matrix metalloproteinase-1 in patients with localized scleroderma. J Dermatol Sci. 2008 Oct;52(1):47–54.PubMedCrossRefGoogle Scholar
  79. 79.
    Johnson W, Jacobe H. Morphea in adults and children cohort II: patients with morphea experience delay in diagnosis and large variation in treatment. J Am Acad Dermatol. 2012;67(5):881–9.PubMedCrossRefGoogle Scholar
  80. 80.
    Nouri S, Jacobe H. Recent developments in diagnosis and assessment of morphea. Curr Rheumatol Rep. 2013;15(2):308.PubMedCrossRefGoogle Scholar
  81. 81.
    Chiu YE, Vora S, Kwon EK, et al. A significant proportion of children with morphea en coup de sabre and Parry-Romberg syndrome have neuroimaging findings. Pediatr Dermatol. 2012;29(6):738–48.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Polcari I, Moon A, Mathes EF, et al. Headaches as a presenting symptom of linear morphea en coup de sabre. Pediatrics. 2014;134(6):1715–9.CrossRefGoogle Scholar
  83. 83.
    Lis-Swiety A, Mierzwinska K, Wodok-Wieczorek K, et al. Coexistence of lichen sclerosus and localized scleroderma in female monozygotic twins. J Pediatr Adolesc Gynecol. 2014;27(6):e133–6.PubMedCrossRefGoogle Scholar
  84. 84.
    Saxton-Daniels S, Jacobe HT. An evaluation of long-term outcomes in adults with pediatric-onset morphea. Arch Dermatol. 2010;146(9):1044–5.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    McNiff JM, Glusac EJ, Lazova RZ, et al. Morphea limited to the superficial reticular dermis: an underrecognized histologic phenomenon. Am J Dermatopathol. 1999;21(4):315–9.PubMedCrossRefGoogle Scholar
  86. 86.
    Fernandez-Flores A, Gatica-Torres M, TinocoFragoso F, et al. Three cases of bullous morphea: histopathologic findings with implications regarding pathogenesis. J Cutan Pathol. 2015;42(2):144–9.PubMedCrossRefGoogle Scholar
  87. 87.
    Chiu HY, Tsai TF. Images in clinical medicine. Keloidal morphea. N Engl J Med. 2011;364(14):e28.PubMedCrossRefGoogle Scholar
  88. 88.
    Wriston CC, Rubin AI, Elenitsas R, et al. Nodular scleroderma: a report of 2 cases. Am J Dermatopathol. 2008;30(4):385–8.PubMedCrossRefGoogle Scholar
  89. 89.
    Fett N, Werth VP. Update on morphea: part II. Outcome measures and treatment. J Am Acad Dermatol. 2011;64(2):231–42. [quiz: 243–4].PubMedCrossRefGoogle Scholar
  90. 90.
    Careta MF, Romiti R. Esclerodermia localizada: espectro clínico e atualização terapêutica. An Bras Dermatol. 2015;90(1):61–72.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2018

Authors and Affiliations

  • Jesus Rodriguez Santamaria
    • 1
    Email author
  • Janyana M. D. Deonizio
    • 1
  • Maira Mitsue Mukai
    • 1
  1. 1.Department of Dermatology of FederalUniversity of Parana - UFPRCuritibaBrazil

Personalised recommendations